About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Resistance to Oral Therapy in Lung Cancer

NCT04546282·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

University Hospital, Montpellier

Age

18–90

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

advanced non-small cell lung cancer stage IIIB/IV
Documentation of activating EGFR mutations (exon 19 deletions or exon 21 L858R substitution mutations) at the time of initial diagnosis
Patient may receive up to one line of third EGFR TKI
Plasma sample testing performed to detect EGFR TKI resistance

You may not be if

Patients have other concurrent cancers

The record

StatusCompleted

PhaseNo phase

Taking part20

StartedJul 2017

UpdatedDec 29, 2020

Conditions

Non Small Cell Lung Cancer

Where1

University Hospital
Montpellier, Hérault, France

Clareo Health | Resistance to Oral Therapy in Lung Cancer